Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Active not recruiting 4Recruiting 2Completed 2Unknown 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

NET 4Endocrine 4Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Renal Cell 20Sarcoma 4Neuroendocrine Tumors 4Neoplasms 4Carcinoma, Medullary 4Carcinoma, Hepatocellular 4Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Kidney Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urethral Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Cancer, Papillary 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Prostatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Melanoma 2Lung Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Neuroendocrine 2Carcinoma 2Adenocarcinoma, Follicular 2Wilms Tumor 1Urologic Neoplasms 1

Interventions

lutetium Lu 177 dotatate 11Magnetic Resonance Spectroscopy 6Specimen Handling 5pembrolizumab 4cabozantinib 4Nivolumab 3Everolimus 3lenvatinib 2avelumab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Temozolomide 2Phantoms, Imaging 2Octreotide 2Lutetium-177 2Ipilimumab 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2toripalimab 1tislelizumab 1telotristat ethyl 1surufatinib 1peposertib 1pazopanib 1fludarabine phosphate 1fludarabine 1entrectinib 1atezolizumab 1Surgical Procedures, Operative 1Salts 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Neuroendocrine Tumors × cabozantinib × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT04079712 2026-04-13

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
17 enrolled 12 charts
EndocrineNETThoracic

Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT05249114 2026-04-13

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Providence Health & Services

Phase 1 Active not recruiting
6 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT04524208 2024-08-13

CABONEN

University Medical Center Goettingen

Phase 2 Active not recruiting
45 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡